Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 31: 1322-1328, 1985;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwarz, S.
Right arrow Articles by Wick, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwarz, S.
Right arrow Articles by Wick, G.

Clinical Chemistry, Vol 31, 1322-1328, Copyright © 1985 by American Association for Clinical Chemistry

Epitope-selective, monoclonal-antibody-based immunoradiometric assays of predictable specificity for differential measurement of choriogonadotropin and its subunits

S Schwarz, P Berger and G Wick

Knowing the epitope specificities of our monoclonal antibodies (MCA) to human choriogonadotropin (hCG), we could design three classes of two- site immunoradiometric assays (IRMA): a combination of two MCA recognizing two separate alpha-epitopes (alpha-MCA) provides a system (i.e., an alpha-IRMA) that measures holo-hCG plus free alpha-subunits plus follitropin, lutropin, and thyrotropin, whereas a beta-IRMA, consisting of two beta-MCA, quantifies holo-hCG plus free beta- subunits. The amount of either of the two subunits can be calculated by subtracting the amount of holo-hCG determined in parallel in a holo-hCG- IRMA. In the latter, one of the alpha- or beta-MCA may be either cross- combined or, preferably, paired with an MCA specific for a conformational epitope. These analytical specificities, predicted from our previously established epitope map of hCG, could be experimentally verified. With these IRMAS we could demonstrate that in certain choriocarcinoma cell lines the earliest and quantitatively predominant tumor marker is the free alpha-subunit. Similar results showing an unbalanced secretion of hCG and its subunits were obtained for patients with related tumors. These findings challenge the present diagnostic practice of relying solely on "beta-hCG" radioimmunoassays and at the same time offer a novel analytical strategy.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Association for Clinical Chemistry.